Cell Therapy Deals and Alliances of 2013 -





Published: March 2014 | Pages: 200 | Format: PDF

 The Cell Therapy Deals and Alliances of 2013 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2013. 

 Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. 

 The initial chapters of this report provide an orientation of 2013's dealmaking and business activities. 

 Chapter 1 provides an overview of the trends in dealmaking during 2013 covering trends by deal type, stage of development, technology type and therapeutic indication. 

 Chapter 2 provides a review of the leading deals during 2013. Deals are listed by headline value, signed by bigpharma and bigbiotech, and most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. 

 Chapter 3 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of 2013 deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

 Chapter 4 provides a comprehensive directory of all partnering deals announced during 2013.  

 The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

 The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2012. 

 In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2013.Cell Therapy Deals and Alliances of 2013 provides the reader with the following key benefits: 

  •  In-depth understanding of recent dealmaking trends during 2013  
  •  Comprehensive access to all deals entered into by the world's biopharma companies during 2013 
  •  Detailed access to actual partnership deals and contracts entered into by the leading fifty bigpharma companies 
  •  Understand the key deal terms companies have agreed in previous deals  
  •  Undertake due diligence to assess suitability of your proposed deal terms for partner companies 

 Report scope 

 Cell Therapy Deals and Alliances of 2013 is intended to provide the reader with an in-depth understanding and access to parthering trends and structure of deals entered into by leading companies worldwide. 

 Cell Therapy Deals and Alliances of 2013 includes: 

  •  Trends in dealmaking in the biopharma industry during 2013 
  •  Comprehensive directory of partnering deals in 2013 
  •  Links to online access to all deals and alliances 
  •  The leading partnering deals by value in 2013 
  •  Most active partnering dealmakers during 2013 

 In Cell Therapy Deals and Alliances of 2013 the partnering deals are listed by: 

  •  Company A-Z 
  •  Headline value 
  •  Stage of development at signing 
  •  Deal component type 
  •  Therapy area 
  •  Technology type 

 Each deal title links via Weblink to an online version of the deal record at Current Agreements and where available, the contract document, providing easy access to each contract document on demand. 

 

 Executive Summary 

    

 Chapter 1 - Trends in dealmaking during 2013 

 

 1.1. Bigpharma dealmaking activity 

 1.2. Partnering by deal type 

 1.3. Partnering by industry sector 

 1.4. Partnering by stage of development 

 1.5. Partnering by technology type 

 1.6. Partnering by therapy area 

 

 Chapter 2 - Leading deals during 2013 


 

 2.1. Introduction 

 2.2. Top deals by value during 2013 

 

 Chapter 3 - Bigpharma deals during 2013 
  

  3.1. Introduction 

  3.2. How to use bigpharma partnering deals 

  3.3. Bigpharma partnering company profiles for 2013 

  Abbott  

  Actavis 

  Actelion 

  Allergan 

  Amgen 

  Aspen Pharmacare 

  Astellas 

  AstraZeneca 

  Baxter International 

  Bayer 

  Biogen Idec 

  Boehringer Ingelheim 

  Bristol-Myers Squibb 

  Celgene  

  CSL  

  Daiichi Sankyo 

  Dainippon Sumitomo 

  Eisai  

  Eli Lilly 

  Endo Pharmaceuticals  

  Forest Laboratories 

  Galderma  

  Gilead Sciences  

  GlaxoSmithKline  

  Grifols  

  Hospira 

  Johnson & Johnson 

  Kyowa Hakko Kirin 

  Lundbeck  

  Menarini 

  Merck & Co 

  Merck KGaA 

  Mitsubishi Tanabe 

  Novartis  

  Novo Nordisk 

  Otsuka 

  Pfizer  

  Purdue 

  Roche  

  Sanofi  

  Servier 

  Shionogi 

  Shire  

  Takeda 

  Teva  

  Valeant 

  Warner Chilcott 

  Watson 

   

 Chapter 4 - Partnering deals directory 2013 

 

 4.1. Introduction  

 4.2. Company A-Z  

 4.3. By deal type 

 4.4. By stage of development 

 4.5. By technology type 

 4.6. By therapy area 

 

  

 

  

 

 TABLE OF FIGURES 

 

 Figure 1: Bigpharma - top 50 - January to December 2013 

 

 Figure 2: Bigpharma deal frequency - 2013 

 

 Figure 3: Partnering by deal type during 2013 

 

 Figure 4: Partnering by industry sector during 2013 

 

 Figure 5: Partnering by stage of development during 2013 

 

 Figure 6: Partnering by technology type during 2013 

 

 Figure 7: Partnering by therapy area during 2013 

 

 Figure 8: Top deals by value during 2013